Picture [iito] Back into Ad 650x80px
Document › Details

PolyTherics Ltd.. (8/20/12). "Press Release: PolyTherics Appoints New Head of Business Development". London.

Organisations Organisation PolyTherics Ltd.
  Group Abzena (Group)
  Organisation 2 Silence Therapeutics plc (LON: SLN)
  Group Silence Therapeutics (Group)
Products Product TheraPEG™ technology
  Product 2 biopharmaceutical
Persons Person Buchner, Georg (Helsinn 201902– Head Licensing + BusDev before PolyTherics + Silence Therapeutics + Novacta + Haptogen)
  Person 2 Burt, John (Abzena 201405– CEO before Antitope + PolyTherics + Thiakis)

PolyTherics Limited ("PolyTherics"), a provider of solutions to enable the development of better biopharmaceuticals, is very pleased to announce the appointment of Dr Georg Buchner as Vice President of Business Development. Georg will work with Jenny Filbey, PolyTherics' business development representative in the USA and CEO John Burt, to further build on PolyTherics' commercial success and to expand the Company's partnering programme.

Georg joins PolyTherics from Silence Therapeutics where he held a similar position. His previous roles include Vice President of Corporate and Business Development at Novacta Biosystems Limited and Director of Business Development at Haptogen Limited, where he led the sale of the company to Wyeth Research. Georg is fluent in Italian and German, he has an MBA from the University of Cambridge and a PhD in Molecular Biology from King's College London.

Record changed: 2020-07-20


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Abzena (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

» top